[First Release]Shanghai Baiyi Medical Technology Co., Ltd. Completes Tens of Millions of Yuan in Series A Financing, Fills the Gap in Full-course Thyroid Disease Management, and Embarks on International Journey

VCBeat learned at the first time that Shanghai Baiyi Medical Technology Co., Ltd. (referred to as "Baiyi Medical") has officially completed a multi-million-yuan RMB A-round strategic financing recently. The institutions participating in this round of financing includeZhongshan Cuiheng Venture CapitalAndHongrun Private Equity Fund。

The funds from this round of financing will be mainly used for the promotion of the company's first independently developed automatic eye sign measurement instrument in the domestic market, post-marketing research, and European CE registration. At the same time, it will further enrich the company’s product portfolio in the field of thyroid-related diseases, accelerate the process of making high-end innovative domestic medical devices accessible nationwide, and provide strong support for Shanghai Baiyi Medical Technology Co., Ltd. to achieve its internationalization strategy.

Shanghai Baiyi Medical Technology Co., Ltd. was founded in 2020 and is located in the core area of Zhangjiang Science City, Shanghai. It is an innovative medical device company focusing on the thyroid single-disease field. The company’s strategic core is to create first-in-class (FIC) and best-in-class (BIC) products that fill clinical gaps, with the aim of establishing an international standard system for the full-course management of thyroid diseases and filling the global gap in this field.

Shanghai Baiyi Medical Technology Co., Ltd.'s core product, the "Automatic Ocular Feature Measuring Instrument," has obtained the Class II medical device registration certificate from the National Medical Products Administration (NMPA). This marks the product's official entry into the industrialization channel as the "gold standard" for thyroid eye disease diagnosis. The product not only earned the world's first innovative medical device certification specifically for assessing thyroid eye disease severity but also successfully made it into Shanghai’s "New and Excellent Medical Device Catalog." Within just four months of its market launch, it quickly gained placement in 25 top-tier tertiary hospitals nationwide, achieving high clinical recognition.

Building on this, Shanghai Baiyi Medical Technology Co., Ltd. further deepens clinical translational cooperation and international exchange. The company collaborates extensively with multiple clinical research centers, focusing on transforming frontline clinical needs into cutting-edge technological solutions, thereby forming a closed-loop R&D system of "clinical needs - technological innovation - application validation."

At the same time, as the only innovative medical device company invited from China, the company successively appeared at the European International Forum on Thyroid Eye Disease and the Cambridge London Technology Forum in the UK, showcasing China's innovative strength in the field of life sciences to the world. Not only has it gained recognition in the domestic market, but it has also attracted widespread attention from the international community, achieving a strategic leap from "Chinese innovation" to "global recognition."

Regarding the acquisition of this round of financing,Du Dong, Chairman of Shanghai Baiyi Medical Technology Co., Ltd."We are very grateful to the two industry investors, Zhongshan Cuiheng Venture Capital and Hongrun Private Equity Fund, for their recognition of Baiyi Medical. This round of financing is the company's first step towards commercialization and internationalization. We hope that with the accelerated push from this round of financing, we can take innovation as the engine, technology as the driver, clinical needs as the foundation, and clinical value as the orientation, further filling the gap in global innovative transformation in China's thyroid-related disease field."

Zhongshan Cuiheng Venture CapitalRepresentation: The track of thyroid disease management where Shanghai Baiyi Medical Technology Co., Ltd. is located is entering a golden period of pharmaceutical-device synergy. On one hand, the rising detection rate of diseases has spurred treatment demand. For instance, 40% of Graves' disease patients develop Thyroid Eye Disease (TED), and these patients require precise diagnostic equipment to assess their condition for formulating drug regimens, forming a "diagnosis-guided treatment" linkage. On the other hand, industrial transformation and policy support pave the way for pharmaceutical-device innovation. By 2030, China's TED drug market and the international TED drug market are expected to reach 450 million USD and 3 billion USD respectively, with substantial demand driving the application of diagnostic devices. These devices serve as tools for pre-medication screening and in-treatment monitoring, ensuring drug efficacy while optimizing regimens, highlighting the closed-loop value of "treatment feeding back into diagnosis."

Hongrun CapitalShanghai Baiyi Medical Technology Co., Ltd. has deeply explored the clinical needs of thyroid single disease, broken through the barriers between basic research and clinical practice, and achieved innovative breakthroughs in translational medicine for thyroid disease solutions. The company's products under development are pioneering, and its product pipeline can cover integrated diagnosis and treatment services in the endocrine field from early screening to diagnosis and postoperative recovery, all of which are essential clinical products. It is believed that, with the support of the Taicang Port Area industrial ecosystem, Shanghai Baiyi Medical Technology Co., Ltd. will achieve even greater success.

Cuiheng Group always adheres to the industrial operation concept of growing together with enterprises, using industrial funds as a link to actively build an industrial ecosystem that combines the roles of "landlord + shareholder," achieving win-win cooperation between the park and enterprises. To date, Cuiheng Group has initiated the establishment of 10 industrial investment funds with a total scale exceeding 4.5 billion yuan. Through investment-driven attraction and integration of investment and recruitment, it has successfully facilitated the settlement of over 30 technology companies in Cuiheng New District.

As the first state-owned enterprise in Taicang to be registered with the Asset Management Association of China, Hongrun Capital seeks out promising investment opportunities during the industrial transformation and upgrading process of the Taicang Port Area. This includes the implementation of high-quality projects, the expansion of potential projects, the listing of mature companies, and fixed asset investments. Furthermore, it aims to secure co-investment opportunities for premium projects and industry relocation opportunities on a national scale. Currently, Hongrun Capital has directly invested in over 20 market-oriented projects, manages funds exceeding 1.8 billion yuan, and oversees assets totaling more than 5 billion yuan. Its investment portfolio already covers the commercial aerospace industry chain and extends into technology sectors such as medical engineering crossover, low-altitude economy, new energy, new materials, and quantum computing.